Search Results

You are looking at 101 - 110 of 226 items for :

  • "osteoporosis" x
Clear All
Free access

Rhonda D Prisby, Joshua M Swift, Susan A Bloomfield, Harry A Hogan and Michael D Delp

Introduction The occurrence of osteoporosis in diabetic individuals has been recognized since the beginning of the twentieth century ( Morrison & Bogan 1927 , Albright & Reifenstein 1948 , Berney 1952 ). However, the observed rates of osteoporosis

Free access

K J Oldknow, V E MacRae and C Farquharson

, Teitelbaum 2000 , Harada & Rodan 2003 , Teitelbaum & Ross 2003 , Karsenty 2006 ). The misregulation of bone remodelling inevitably results in bone loss and disease and the most common, by far, is osteoporosis. Considering the sheer size and dynamic

Free access

S Mohan and D J Baylink

Introduction The risk of developing senile osteoporosis in men and postmenopausal osteoporosis in women is, in large part, determined by the amount of bone mass accumulated during the active growth phases early in life. In terms of

Free access

Anyonya R Guntur and Clifford J Rosen

transcription factors, including Ppar γ . As noted, chondrocyte-specific deletion of Pten resulted in the appearance of marrow adipocytes ( Hsieh et al . 2009 ). These findings have significant clinical implications. First, in age-related osteoporosis

Free access

Madhusmita Misra and Anne Klibanski

an extraordinarily long half-life, which has raised concerns regarding their use in adolescents and young women of reproductive age. At this time, bisphosphonate use should be limited to women with osteoporosis who are having fractures and should not

Restricted access

Guillaume Mabilleau, Benoit Gobron, Aleksandra Mieczkowska, Rodolphe Perrot and Daniel Chappard

, Yokogawa et al. 2001 ). The current gold standard medication for treating post-menopausal osteoporosis is represented by bisphosphonates and as such, we thought to also ascertain how the two new molecules above compared with alendronate. The main goals

Free access

Rhonda D Prisby

may influence bone mass via NO signaling in vascular endothelial cells ( Prisby et al. 2013 ). Enhanced blood flow following intermittent PTH administration has been documented. For example, post-menopausal women with osteoporosis experienced

Open access

J Jeyabalan, M Shah, B Viollet, J P Roux, P Chavassieux, M Korbonits and C Chenu

to the changes seen during ageing and osteoporosis, suggesting an altered bone remodelling at basal level in these mice. To determine the cause of the low bone mass in Ampkα1 −/− mice and whether bone remodelling is affected in these mice at basal

Free access

John N Stabley, Rhonda D Prisby, Bradley J Behnke and Michael D Delp

from several studies also indicate positive associations between vascular calcification and osteoporosis or low BMD ( Hak et al . 2000 , Reddy et al . 2008 , Adragao et al . 2009 , Choi et al . 2009 , Hyder et al . 2009 , Bandeira et al

Free access

Jonathan H Gooi, Ling Yeong Chia, Nicole C Walsh, Morten A Karsdal, Julian M W Quinn, T John Martin and Natalie A Sims

high level of bone turnover, and hormonal and other features that do not reflect those of adult patients with osteoporosis, who would most commonly be treated with PTH anabolic therapy (Teriparatide). To explore further the influence of transient